Australia's most trusted
source of pharma news
Tuesday, 29 April 2025
Posted 15 September 2023 AM
Clinect has shone a light on why its epilepsy drug Zyamis has stalled in the post-PBAC process in a new submission to the reimbursement committee.
The Melbourne-headquartered company supplies a range of products in Australia and New Zealand via strategic partnering and product acquisition however it has struggled to secure government subsidy for Zyamis under the right terms.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.